JP2017524715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524715A5 JP2017524715A5 JP2017507739A JP2017507739A JP2017524715A5 JP 2017524715 A5 JP2017524715 A5 JP 2017524715A5 JP 2017507739 A JP2017507739 A JP 2017507739A JP 2017507739 A JP2017507739 A JP 2017507739A JP 2017524715 A5 JP2017524715 A5 JP 2017524715A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding portion
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1414270.7A GB201414270D0 (en) | 2014-08-12 | 2014-08-12 | Antibodies |
| GB1414270.7 | 2014-08-12 | ||
| GB201422614 | 2014-12-18 | ||
| GB1422614.6 | 2014-12-18 | ||
| GBGB1507541.9A GB201507541D0 (en) | 2015-05-01 | 2015-05-01 | Antibodies |
| GB1507541.9 | 2015-05-01 | ||
| PCT/EP2015/068598 WO2016023960A1 (en) | 2014-08-12 | 2015-08-12 | Combination therapies with anti cd40 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524715A JP2017524715A (ja) | 2017-08-31 |
| JP2017524715A5 true JP2017524715A5 (enExample) | 2018-09-27 |
| JP6654187B2 JP6654187B2 (ja) | 2020-02-26 |
Family
ID=53836090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507739A Active JP6654187B2 (ja) | 2014-08-12 | 2015-08-12 | 抗ｃｄ４０抗体を用いた併用療法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11149090B2 (enExample) |
| EP (3) | EP3552665A3 (enExample) |
| JP (1) | JP6654187B2 (enExample) |
| KR (1) | KR102443258B1 (enExample) |
| CN (3) | CN106573981A (enExample) |
| AU (1) | AU2015303164B2 (enExample) |
| CA (1) | CA2957146A1 (enExample) |
| CL (1) | CL2017000335A1 (enExample) |
| CO (1) | CO2017001317A2 (enExample) |
| CR (1) | CR20170096A (enExample) |
| DK (1) | DK3180087T3 (enExample) |
| EA (1) | EA201790339A1 (enExample) |
| EC (1) | ECSP17008984A (enExample) |
| ES (1) | ES2725463T3 (enExample) |
| IL (1) | IL250512B (enExample) |
| MA (1) | MA47472A (enExample) |
| MX (1) | MX382549B (enExample) |
| NI (1) | NI201700015A (enExample) |
| PE (1) | PE20170680A1 (enExample) |
| PH (1) | PH12017500229A1 (enExample) |
| SG (1) | SG11201701070WA (enExample) |
| SV (1) | SV2017005380A (enExample) |
| UA (1) | UA119783C2 (enExample) |
| WO (1) | WO2016023960A1 (enExample) |
| ZA (1) | ZA201701126B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| JP6367836B2 (ja) | 2013-02-07 | 2018-08-01 | ザ ジェネラル ホスピタル コーポレイション | Ｔ制御性細胞の増殖または枯渇方法 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| EP3447075B1 (en) | 2015-05-15 | 2023-08-09 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| US20190135929A1 (en) | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| US10323090B2 (en) | 2015-11-18 | 2019-06-18 | Merck Sharp & Dohme Corp. | PD1 and/or LAG3 binders |
| SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| AU2017263833B2 (en) * | 2016-05-13 | 2023-08-03 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| CA3030636A1 (en) | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| EP3532505A4 (en) | 2016-10-25 | 2019-12-25 | Urogen Pharma Ltd. | BODY CAVES IMMUNODULATING TREATMENTS |
| MX2019005089A (es) * | 2016-11-02 | 2019-09-10 | Apexigen Inc | Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso. |
| EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| ES2902670T3 (es) * | 2017-01-13 | 2022-03-29 | Taizhou Hanzhong Biopharmaceutics Inc | Anticuerpo monoclonal contra PD-1 y aplicaciones del mismo |
| CN110636861B (zh) * | 2017-03-03 | 2022-07-08 | 詹森生物科技公司 | 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法 |
| CA3071217A1 (en) | 2017-08-31 | 2019-03-07 | Multimmune Gmbh | Hsp70 based combination therapy |
| BR112020018761A2 (pt) * | 2018-03-13 | 2020-12-29 | Hibercell, Inc. | Imunoterapia combinada com beta-glucano e agonista de cd40 |
| EP3807320A4 (en) * | 2018-06-12 | 2022-03-23 | BioNTech US Inc. | POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS |
| CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| WO2020039321A2 (en) * | 2018-08-20 | 2020-02-27 | Pfizer Inc. | Anti-gdf15 antibodies, compositions and methods of use |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| IL283279B2 (en) * | 2018-11-23 | 2025-08-01 | Strike Pharma Ab | Bi-specific conjugates |
| AU2019389354A1 (en) * | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| CN113939535A (zh) * | 2019-05-28 | 2022-01-14 | 詹森生物科技公司 | 提供抗cd40抗体的安全施用的方法 |
| EP4027998A1 (en) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| JP2023509902A (ja) * | 2019-12-27 | 2023-03-10 | インターオリゴ・コーポレイション | 癌治療用免疫抗癌組成物 |
| GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CN113861292A (zh) * | 2020-06-30 | 2021-12-31 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| KR20230165276A (ko) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
| JP2024525475A (ja) | 2021-06-29 | 2024-07-12 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションを促進するように操作された免疫細胞及びその使用 |
| US20240400706A1 (en) * | 2021-10-15 | 2024-12-05 | The Rockefeller University | Combination of anti-cd40 antibody and il-15 for treating cancer |
| JP2024539940A (ja) * | 2021-10-26 | 2024-10-31 | ナビキュア バイオファーマシューティカルズ リミテッド | がん及び感染症に対する組み合わせ療法 |
| KR20250029883A (ko) | 2022-06-23 | 2025-03-05 | 엘리게이터 바이오사이언스 에이비 | 조합 요법 |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1996006641A1 (en) | 1994-08-29 | 1996-03-07 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| JP4430303B2 (ja) | 2000-12-12 | 2010-03-10 | アリゲーター・バイオサイエンス・アーベー | タンパク質機能のインビトロ分子進化方法 |
| ATE374214T1 (de) | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2003097834A2 (en) | 2002-05-17 | 2003-11-27 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| RU2006141632A (ru) | 2004-04-27 | 2008-06-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) | Антагонистические моноклональные анти-cd40-антитела и способы их применения |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| JP5027804B2 (ja) | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス，インコーポレーテッド | ヒト化抗ｃｄ４０抗体およびその使用方法 |
| GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| CA2712989C (en) | 2008-01-23 | 2015-10-27 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| CA2735421A1 (en) | 2008-08-29 | 2010-03-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
| WO2011034904A1 (en) * | 2009-09-16 | 2011-03-24 | E. I. Du Pont De Nemours And Company | Chiller apparatus containing trans-1,1,1,4,4,4-hexafluoro-2-butene and methods of producing cooling therein |
| GB201006096D0 (en) | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US10533054B2 (en) * | 2013-01-31 | 2020-01-14 | Thomas Jefferson University | Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system |
| HK1221409A1 (zh) | 2013-12-20 | 2017-06-02 | 豪夫迈．罗氏有限公司 | 抗ang2抗体和cd40激动剂的组合疗法 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| SG11201708223QA (en) | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| SI3303395T1 (sl) | 2015-05-29 | 2020-03-31 | Abbvie Inc. | Protitelesa proti CD40 in njihove uporabe |
| PE20180315A1 (es) | 2015-06-29 | 2018-02-09 | Bristol Myers Squibb Co | Anticuerpos para cd40 |
| MX2017016502A (es) | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
-
2015
- 2015-08-12 US US15/329,402 patent/US11149090B2/en active Active
- 2015-08-12 CN CN201580043161.1A patent/CN106573981A/zh active Pending
- 2015-08-12 KR KR1020177005821A patent/KR102443258B1/ko active Active
- 2015-08-12 ES ES15750051T patent/ES2725463T3/es active Active
- 2015-08-12 MX MX2017001864A patent/MX382549B/es unknown
- 2015-08-12 UA UAA201701452A patent/UA119783C2/uk unknown
- 2015-08-12 CN CN202111420044.6A patent/CN114099671A/zh active Pending
- 2015-08-12 EP EP19161728.1A patent/EP3552665A3/en active Pending
- 2015-08-12 CR CR20170096A patent/CR20170096A/es unknown
- 2015-08-12 EA EA201790339A patent/EA201790339A1/ru unknown
- 2015-08-12 SG SG11201701070WA patent/SG11201701070WA/en unknown
- 2015-08-12 EP EP25194883.2A patent/EP4653463A2/en active Pending
- 2015-08-12 EP EP15750051.3A patent/EP3180087B1/en active Active
- 2015-08-12 CN CN202411444693.3A patent/CN119280407A/zh active Pending
- 2015-08-12 WO PCT/EP2015/068598 patent/WO2016023960A1/en not_active Ceased
- 2015-08-12 JP JP2017507739A patent/JP6654187B2/ja active Active
- 2015-08-12 AU AU2015303164A patent/AU2015303164B2/en active Active
- 2015-08-12 CA CA2957146A patent/CA2957146A1/en active Pending
- 2015-08-12 DK DK15750051.3T patent/DK3180087T3/da active
- 2015-08-12 MA MA047472A patent/MA47472A/fr unknown
- 2015-08-12 PE PE2017000203A patent/PE20170680A1/es unknown
-
2017
- 2017-02-07 PH PH12017500229A patent/PH12017500229A1/en unknown
- 2017-02-07 SV SV2017005380A patent/SV2017005380A/es unknown
- 2017-02-08 IL IL250512A patent/IL250512B/en unknown
- 2017-02-09 NI NI201700015A patent/NI201700015A/es unknown
- 2017-02-09 CL CL2017000335A patent/CL2017000335A1/es unknown
- 2017-02-10 EC ECIEPI20178984A patent/ECSP17008984A/es unknown
- 2017-02-10 CO CONC2017/0001317A patent/CO2017001317A2/es unknown
- 2017-02-15 ZA ZA2017/01126A patent/ZA201701126B/en unknown
-
2021
- 2021-09-15 US US17/475,592 patent/US20210403589A1/en not_active Abandoned
-
2023
- 2023-12-13 US US18/538,429 patent/US20240228643A9/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524715A5 (enExample) | ||
| JP2016537383A5 (enExample) | ||
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2019510733A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| WO2019086497A3 (en) | Combination therapy with targeted ox40 agonists | |
| JP2018516911A5 (enExample) | ||
| NZ752294A (en) | Cd3 binding antibodies | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| EP3552665A3 (en) | Antibodies | |
| MX2018014950A (es) | Terapia de combinacion. | |
| MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2014205674A5 (enExample) | ||
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| WO2015200806A3 (en) | Humanized anti-tau antibodies | |
| RU2017145558A (ru) | Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака | |
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| JP2020502271A5 (enExample) | ||
| MX2020006116A (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t. | |
| WO2016090024A4 (en) | Combination therapy for treatment of cancer |